The sales of pharmaceutical preparations acting on the respiratory system in the US have shown significant fluctuations over the past decade. From a high of 13.751 billion USD in 2015, the market experienced a sharp decline, reaching a low of 9.8759 billion USD in 2020. Recent years showed a moderate recovery, with sales standing at 11.253 billion USD in 2023. The year-on-year variations indicate highly variable trends with large drops in 2020 and significant gains in 2021 followed by negative trends in subsequent years. The compound annual growth rate (CAGR) over the last five years indicates an average annual decrease of 1.84%.
Future trends to watch for include:
- Continued slow decline with an estimated CAGR of -1.64% over the next five years.
- Innovations in respiratory treatments may impact market dynamics positively.
- Regulatory changes and healthcare policies could play a significant role in market fluctuations.
- Potential market expansion through new therapeutic solutions and wider patient access.